Authors : Kavita Wadde, Kavita Wadde, Jayant Landge, Jayant Landge, Sandip Rathod, Sandip Rathod, Ashwini Chapane, Ashwini Chapane
DOI : 10.18231/j.jooo.2020.010
Volume : 6
Issue : 1
Year : 2020
Page No : 36-40
Central giant cell granuloma (CGCG) is an uncommon, benign, and proliferative lesion of the jaw with an unknown aetiology, was first described by Jaffe in 1953.The lesion is found predominantly in children and young adults, with more than 60% of all cases occurring before the age of 30 years. The female: male ratio is 2:1. Lesions are more common in the anterior region of the jaws, and mandibular lesions frequently extend across the midline. CGCG can be difficult to diagnose from other lesion of oral cavity like Hyperparathyroid tumour, Ameloblastoma, Odontogenic myxoma, Haemangioma, Cherubism, Central odontogenic fibroma, Aneurysmal bone cyst, Traumatic bone cyst. Numerous treatment modalities given in literature from non–surgical to surgical. This paper intends to focus on diagnosis, clinical presentation and different management options of CGCG. So our aim was to evaluate the response of treatment of CGCG to intralesional injection.
Keywords: Central giant cell granuloma, Midline, Intralesional steroid, Phase I therapy, Phase II therapy.